胸苷激酶1在白血病患者化疗过程中的临床意义探讨  

Clinical significance of thymidine kinase 1 in chemotherapy of leukemia

作　　者：曾智杰[1] 欧阳文婷[1] 孙艳虹[1] 蔡小华 

机构地区：[1]中山大学附属第一医院检验科,广东广州510080 [2]中山大学附属第一医院黄埔院区检验科,广东广州510182

出　　处：《分子诊断与治疗杂志》2009年第1期28-30,共3页Journal of Molecular Diagnostics and Therapy

基　　金：广东省科技计划项目(071122060017)

摘　　要：目的利用免疫印迹增强化学发光法检测白血病患者化疗过程中血清胸苷激酶1(sTK1)水平,分析sTK1在评估白血病患者治疗效果以及对治疗方案的指导价值。方法分别对22例血液肿瘤治疗未缓解患者,20例治疗部分缓解患者,8例治疗完全缓解患者和29例健康人sTK1水平进行测定。结果未缓解组sTK1平均水平为(4.10±1.32)pmol/L,部分缓解组sTK1平均水平为(1.73±0.54)pmol/L,完全缓解组sTK1平均水平为(0.96±0.45)pmol/L,健康人对照组为(0.79±0.47)pmol/L。治疗未缓解患者组sTK1平均水平与完全缓解及部分缓解组有显著差异(P<0.01,P<0.01),且明显高于健康人组。完全缓解组肿瘤患者sTK1水平与健康对照组sTK1水平相差不大(P>0.05)。结论sTK1的含量可用于血液肿瘤化疗效果的评估,以及指导临床进行化疗方案的调整。Objective To analyze the practiced value of serum thymidine kinase 1 in evaluating the therapeutic effects and adjusting treatment plan in leukemia. Methods The serum thymidine kinase 1 of 79 samples including patients with hematologic malignancy(22 no-remission, 20 partial remission, 8 complete remission) and 29 healthy persons were detected by western-blotting enhanced chemiluminescence metho. Results The concentrations of serum thymidine kinase 1 were (4.10±1.32)pmol/L, (1.73±0.54) pmol/L, (0.96± 0.45) pmol/L, (0.79±0.47) pmol/L in no-remission group, partial remission group, complete remission group and healthy group separately. There had significant difference between partial or complete remission group and no-remission group which result was higher than that in healthy group(P<0.01, P<0.01). There were little difference between complete remission group and healthy group(P>0.05). Conclusion The serum thymidine kinase 1 can be used for evaluating the chemotherapeutic effects and providing guidance for clinical adjusting treatment plan in patients with hematologic malignancy.

关 键 词：胸苷激酶 细胞增殖标志物 免疫印迹增强化学发光法 

分 类 号：R733.7[医药卫生—肿瘤]